Clinical Trials

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03221426 2026-03-09

KEYNOTE-585

1,007 enrolled 25 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

NCT04332653 2026-03-09

NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

BreastGastrointestinalGynecologicThoracic

215 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Thoracic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

462 enrolled 30 charts

Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT04221945 2026-02-20

KEYNOTE-A18

1,060 enrolled 30 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT04738487 2026-02-20

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

1,264 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03829332 2026-02-19

LEAP-007

623 enrolled 26 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02684292 2026-02-18

MK-3475-204

304 enrolled 2 FDA

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT03820986 2026-02-09

LEAP-003

674 enrolled 21 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03598608 2026-02-05

MK-4280-003

137 enrolled

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03713593 2026-02-05

LEAP-002

794 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03829319 2026-02-05

LEAP-006

761 enrolled 31 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03898180 2026-02-05

LEAP-011

505 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT04700124 2026-02-05

KEYNOTE-B15

808 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT04776148 2026-02-05

MK-7902-017

563 enrolled 32 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT03040999 2026-02-04

KEYNOTE-412

804 enrolled 20 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

617 enrolled 29 charts 1 FDA

Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03867084 2026-02-04

KEYNOTE-937

959 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT04889118 2025-12-23

LEAP-003

131 enrolled 16 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

89 enrolled 14 charts

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04704219 2025-12-03

KEYNOTE-B61

160 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04165083 2025-11-26

MK-3475-01B

102 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03010176 2025-10-29

MK-1454-001

Phase 1 Completed

156 enrolled 20 charts

Lymphoid

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma

NCT04700072 2025-10-28

KEYMAKER-U02

56 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05665595 2025-10-15

KEYVIBE-010

1,594 enrolled 12 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02964013 2025-10-14

KEYVIBE-001

Phase 1 Completed

474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04934722 2025-10-01

KEYNOTE-991

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03062358 2025-09-30

MK-3475-394

453 enrolled 22 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT05064059 2025-09-17

MK-4280A-007

441 enrolled 24 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

NCT04716933 2025-09-09

LEAP-006

201 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03715205 2025-08-29

Keynote-593

Phase 4 Completed

150 enrolled 14 charts

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

100 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03322540 2025-08-22

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

154 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03361865 2025-08-22

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

93 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT03374488 2025-08-22

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

84 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Transitional Cell

NCT05007106 2025-08-14

KEYVIBE-005